13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

STE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for STERIS plc (STE), a Healthcare sector company. STE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2026), STERIS plc reports quarterly revenue of $1.6B, net income of $220.2M, an operating margin of 19.9%. Top institutional holders of STE by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. STE trades on the NYSE exchange and files with the SEC under CIK 1757898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STERIS plc directly from SEC EDGAR.

Revenue

Q4 2026

$1.6B

Net Income

Q4 2026

$220.2M

Free Cash Flow

Q4 2026

$245.2M

Operating Margin

Q4 2026

19.9%

D/E Ratio

Q4 2026

0.27

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.7% YoY
$5.94BFY 2026
FY22 $4.22BFY24 $5.14BFY25 $5.46BFY26 $5.94B

Net Income

+27.3% YoY
$782.3MFY 2026
FY22 $243.9MFY24 $378.2MFY25 $614.6MFY26 $782.3M

Operating Income

+27.1% YoY
$1.10BFY 2026
FY22 $477.8MFY24 $836.1MFY25 $866.6MFY26 $1.10B

EPS (Diluted)

+27.9% YoY
$7.93FY 2026
FY22 $2.48FY24 $3.81FY25 $6.20FY26 $7.93

Total Assets

+5.8% YoY
$10.74BFY 2026
FY22 $11.42BFY24 $11.06BFY25 $10.15BFY26 $10.74B

Total Debt

-5.5% YoY
$1.93BFY 2026
FY22 $3.09BFY24 $3.21BFY25 $2.04BFY26 $1.93B

Op. Cash Flow

+16.8% YoY
$1.34BFY 2026
FY22 $684.8MFY24 $973.3MFY25 $1.15BFY26 $1.34B

AI Insight: STE Financial Trends

STERIS delivered accelerating profitability and debt reduction, with Q1 2026 operating income reaching $317M (+36% vs. Q2 2024) while total debt fell 16% to $1.9B.

Operating income expanded 70% from $186M in Q2 2024 to $317M in Q1 2026; operating margin widened from 14.5% to 20.0%.

Total debt declined 16.4% over two years (Q2 2024: $2,316M → Q1 2026: $1,932M), reducing leverage while equity grew to $7,184M.

Net income surged 51.7% from $145M in Q2 2024 to $220M in Q1 2026, demonstrating strong bottom-line leverage.

Revenue growth decelerated; Q1 2026 at $1,588M marks only 2.0% sequential growth after prior quarter's 2.5%, suggesting potential plateau.

Operating cash flow volatile: Q2 2025 spike to $420M not sustained; Q1 2026 at $335M suggests normalization, monitor consistency.

AI Insight: STE Ratio Trends

STERIS achieved record profitability in Q1 2026, with operating margin reaching 19.9% and ROIC expanding to 13.9%, while maintaining a lean 0.27x debt-to-equity ratio.

Operating margin expanded 540bp from Q2 2024 (14.5%) to Q1 2026 (19.9%), driven by operational leverage and margin improvement across cycles.

ROIC climbed 530bp from Q2 2024 (8.6%) to Q1 2026 (13.9%), reflecting stronger capital efficiency and return generation.

Debt-to-equity ratio compressed from 0.36x in Q2 2024 to 0.27x by Q1 2026, signaling deleveraging and improved financial flexibility.

Q1 2025 margin dipped to 14.6%, marking the only material pullback in the 18-month trend; monitor quarterly volatility and seasonality patterns.

Get alerted when STE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STERIS plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of STE

Put STE on your watchlist

Track score changes the day STERIS plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is STE a good stock to buy?

13F Pro's AI-powered analysis of STERIS plc (STE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STE are available on the STE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STERIS plc's investment landscape.